Geng Liang-Quan

Learn More
BACKGROUND Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for severe aplastic anemia (SAA). However, graft failure and graft-versus-host disease (GVHD) are major causes of the early morbidity in Allo-HSCT. METHODS To reduce graft failure and GVHD, we treated fifteen patients with SAA using high- dose of HSCT with(More)
  • 1